PhD, Medicine, University of Cambridge
MSPH, Global Disease Epidemiology and Control and Vaccine Science and Policy, Johns Hopkins Bloomberg School of Public Health
AB, Government (International Relations), Harvard College.
Megan Carey is an infectious disease epidemiologist and public health policy professional with over a decade of experience in vaccine science and policy, antimicrobial resistance (AMR), and public health strategy. Her work focuses on translating evidence into policy, with a particular emphasis on using genomic data to inform public health decisions and understanding the impact of vaccines on AMR.
At MMGH, Megan has worked closely with the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) Secretariat to GRADE evidence, synthesize new data, and draft background documents and position papers for new vaccines, including dengue vaccines, RSV vaccines and monoclonal antibodies, and typhoid conjugate vaccines (TCVs). She is also Associate Director of AMR Strategy and Epidemiology at the International AIDS Vaccine Initiative (IAVI), where she is developing a cross-institutional AMR strategy, and a Postdoctoral Policy Fellow at the London School of Hygiene and Tropical Medicine, contributing to the AMRnet project and serving on the AMR Centre management committee. Additionally, Megan is an Academic Editor for PLOS Global Public Health.
Previously, Megan consulted for the World Health Organization (WHO), where she developed the TCV research agenda, updated SAGE on the latest TCV data, and developed guidance on measuring the impact of licensed and pipeline vaccines on AMR. She co-founded the Global Typhoid Genomics Consortium, which promotes the use of genomic data to track antimicrobial resistance and guide public health interventions. Previously, Megan worked at the Bill & Melinda Gates Foundation, where she was a Program Officer on the Enteric and Diarrheal Disease team. Megan managed a portfolio of over 50 grants (~$100M) focused on typhoid, rotavirus, and cholera, including large multisite clinical surveillance studies, clinical trials of investigational vaccine candidates, environmental surveillance and transmission dynamics, infectious disease modelling, advocacy and communications, and was the typhoid strategy lead. Megan also initiated the WomenLift Health program to train women leaders in global health
Vaccine science and policy, Antimicrobial resistance, Genomic epidemiology, Infectious disease epidemiology, Public health strategy, Data visualization, Vaccine impact assessment